84 related articles for article (PubMed ID: 20201734)
21. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Marshall JL
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer: from molecular pathogenesis to targeted therapy.
Strimpakos A; Saif MW; Syrigos KN
Cancer Metastasis Rev; 2008 Sep; 27(3):495-522. PubMed ID: 18427734
[TBL] [Abstract][Full Text] [Related]
23. Targeted tailored management of the breast cancer patient at risk for harboring a germline mutation-current trends affecting the selection of patients considering surgical prophylaxis for breast cancer.
Silva E
Breast J; 2009; 15 Suppl 1():S76-80. PubMed ID: 19775334
[TBL] [Abstract][Full Text] [Related]
24. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
[TBL] [Abstract][Full Text] [Related]
25. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
[TBL] [Abstract][Full Text] [Related]
26. The role of chemotherapy in the treatment of adenocarcinoma of the pancreas.
Fennelly D; Kelsen DP
Hepatogastroenterology; 1996; 43(8):356-62. PubMed ID: 8714228
[TBL] [Abstract][Full Text] [Related]
27. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic cancer: from molecular signature to target therapy.
Longo R; Cacciamani F; Naso G; Gasparini G
Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic cancer: progress in cancer therapy.
Pierantoni C; Pagliacci A; Scartozzi M; Berardi R; Bianconi M; Cascinu S
Crit Rev Oncol Hematol; 2008 Jul; 67(1):27-38. PubMed ID: 18356073
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic deregulation of DNA repair and its potential for therapy.
Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R
Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858
[TBL] [Abstract][Full Text] [Related]
32. The evolution of treatment strategies: aiming at the target.
Dinh P; Sotiriou C; Piccart MJ
Breast; 2007 Dec; 16 Suppl 2():S10-6. PubMed ID: 17764940
[TBL] [Abstract][Full Text] [Related]
33. Radionuclide imaging of drug delivery for patient selection in targeted therapy.
Heskamp S; van Laarhoven HW; van der Graaf WT; Oyen WJ; Boerman OC
Expert Opin Drug Deliv; 2014 Feb; 11(2):175-85. PubMed ID: 24400729
[TBL] [Abstract][Full Text] [Related]
34. Targeted Approach Succeeds in Pancreatic Cancer.
Cancer Discov; 2020 Jun; 10(6):753. PubMed ID: 32273294
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?
Grapsa D; Saif MW; Syrigos K
World J Gastrointest Oncol; 2015 Oct; 7(10):172-7. PubMed ID: 26483872
[TBL] [Abstract][Full Text] [Related]
36. Imaging-based Risk Scores for Treatment Selection in Early Pancreatic Cancer: A Step Forward for Tailored Treatment.
Pandharipande PV; Anderson MA
Radiology; 2020 Sep; 296(3):552-553. PubMed ID: 32692283
[No Abstract] [Full Text] [Related]
37. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells.
Eling N; Reuter L; Hazin J; Hamacher-Brady A; Brady NR
Oncoscience; 2015; 2(5):517-32. PubMed ID: 26097885
[TBL] [Abstract][Full Text] [Related]
38. Whole genomes redefine the mutational landscape of pancreatic cancer.
Waddell N; Pajic M; Patch AM; Chang DK; Kassahn KS; Bailey P; Johns AL; Miller D; Nones K; Quek K; Quinn MC; Robertson AJ; Fadlullah MZ; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Wilson PJ; Markham E; Cloonan N; Anderson MJ; Fink JL; Holmes O; Kazakoff SH; Leonard C; Newell F; Poudel B; Song S; Taylor D; Waddell N; Wood S; Xu Q; Wu J; Pinese M; Cowley MJ; Lee HC; Jones MD; Nagrial AM; Humphris J; Chantrill LA; Chin V; Steinmann AM; Mawson A; Humphrey ES; Colvin EK; Chou A; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Pettitt JA; Merrett ND; Toon C; Epari K; Nguyen NQ; Barbour A; Zeps N; Jamieson NB; Graham JS; Niclou SP; Bjerkvig R; Grützmann R; Aust D; Hruban RH; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Falconi M; Zamboni G; Tortora G; Tempero MA; ; Gill AJ; Eshleman JR; Pilarsky C; Scarpa A; Musgrove EA; Pearson JV; Biankin AV; Grimmond SM
Nature; 2015 Feb; 518(7540):495-501. PubMed ID: 25719666
[TBL] [Abstract][Full Text] [Related]
39. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.
Dal Molin M; Zhang M; de Wilde RF; Ottenhof NA; Rezaee N; Wolfgang CL; Blackford A; Vogelstein B; Kinzler KW; Papadopoulos N; Hruban RH; Maitra A; Wood LD
Clin Cancer Res; 2015 Apr; 21(8):1944-50. PubMed ID: 25623214
[TBL] [Abstract][Full Text] [Related]
40. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.
Muniz VP; Askeland RW; Zhang X; Reed SM; Tompkins VS; Hagen J; McDowell BD; Button A; Smith BJ; Weydert JA; Mezhir JJ; Quelle DE
Genes Cancer; 2013 Jul; 4(7-8):273-84. PubMed ID: 24167655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
